IDEXX Laboratories (IDEXX Laboratories) Cash And Cash Equivalents : $454 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Cash And Cash Equivalents?

IDEXX Laboratories's quarterly cash and cash equivalents increased from Jun. 2023 ($132.84 Mil) to Sep. 2023 ($331.70 Mil) and increased from Sep. 2023 ($331.70 Mil) to Dec. 2023 ($453.93 Mil).

IDEXX Laboratories's annual cash and cash equivalents declined from Dec. 2021 ($144.45 Mil) to Dec. 2022 ($112.55 Mil) but then increased from Dec. 2022 ($112.55 Mil) to Dec. 2023 ($453.93 Mil).

IDEXX Laboratories Cash And Cash Equivalents Historical Data

The historical data trend for IDEXX Laboratories's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Cash And Cash Equivalents Chart

IDEXX Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

90.33

383.93

144.45

112.55

453.93

IDEXX Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															112.55	111.37	132.84	331.70	453.93

IDEXX Laboratories Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

IDEXX Laboratories (NAS:IDXX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

IDEXX Laboratories Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEXX Laboratories (IDEXX Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

IDXX:Mexico IX1:Germany I1DX34:Brazil IDXX:Austria

Address

One IDEXX Drive, Westbrook, ME, USA, 04092

Website

https://www.idexx.com

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.

Executives

James F Polewaczyk	officer: Corporate Vice President	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky	director, officer: President and CEO	ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers	director, officer: President & CEO	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt	director	CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin	director	7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley	director	C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak	director	C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg	officer: EVP, GC & Corporate Secretary	EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek	director	6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451